ACIP review of the hepatitis B birth dose vaccination remains a grave concern - Please read more here.

Site Search

You searched for "hepatitis D"

  • Eiger Presents Clinical Trial Results at The Liver Meeting Digital Experience™ 2020

    By Beatrice Zovich The 2020 meeting of the American Association for the Study of Liver Diseases (AASLD) in November offered the opportunity for scientists from industry and academia to present their findings from clinical trials, studying new medications for hepatitis B and D. Two such presentations were given by Eiger BioPharmaceuticals, Inc. who presented their findings about how well their medications peginterferon lambda and lonafarnib work, both independently and in combination, to treat hepatitis delta virus (HDV) and halt liver fibrosis. The results are promising and offer hope for those affected by HDV. The two medicines under investigation in these studies work in different ways. Lonafarnib works by blocking farnesyl transferase, an enzyme involved in prenylation, the modification of proteins that is necessary for the life cycle of HDV. Peginterferon lambda, on the other hand, triggers immune responses that are crucial for host protection during viral infections. Lambda can also target liver cells accurately, thus reducing the effects of inadvertently targeting central nervous system cells and making it more tolerable to those taking it (Eiger, 2020). Eiger’s first study examined how well peginterferon lambda and lonafarnib (known as LIFT - Lambda InterFeron combo Therapy) work together to lower levels of HDV RNA, 24 weeks post-treatment (Eiger, 2020). This was a Phase 2 study. Lambda was administered at a dosage of 180 mcg once weekly, in combination with 50 mg of Lonafarnib and 100 mg of ritonavir given twice daily, for 24 weeks. The results of this study found that 77% of the 26 participants saw their HDV RNA levels decline and reach a level that was either undetectable or below the level of quantification. 23% of these participants were able to maintain these levels for 24 weeks after treatment had ended. Both tenofovir and entecavir were started prior to treatment for management of HBV. The observed side effects of this regimen were mild to moderate

    http://www.hepb.org/blog/eiger-presents-clinical-trial-results-liver-meeting-digital-experience-2020/
  • 292 Million People Worldwide Have Hepatitis B - So Why Do We Feel Alone?

    … this vaccine is often unavailable and out-of-reach financially in rural Africa and Asia, which is why chronic hepatitis B rates remain stubbornly high and are projected to remain unchanged. To successfully combat hepatitis B, communities need to launch campaigns that combat stigma and teach how to prevent the spread of the disease through education and immunization. They need the resources to test people for hepatitis B and vaccinate those who need it. They also need to teach healthcare providers how to treat patients with liver damage. Fortunately, we have started to see change. On May 28, 2016, at the United Nations World Health Assembly, 194 countries made a historic commitment to eliminate viral hepatitis by 2030. The Global Health Sector Strategy for Viral Hepatitis pledges to reduce deaths from hepatitis B and C by 65 percent and increase treatment by 80 percent. This action is the greatest global commitment to viral hepatitis ever taken. On July 28, 2016, a campaign called NOhep, the first global movement to eliminate viral hepatitis, launched on World Hepatitis Day by the World Hepatitis Alliance. This day was chosen to mark the birthday of Baruch S. Blumberg, MD, D.Phil, who won the Nobel Prize in Medicine for the discovery of the hepatitis B virus. Many of our partners and other organizations around the world are raising awareness to highlight World Hepatitis Day. Here are some of the activities you can support. WHO - The World Health Organization is celebrating World Hepatitis Day through its theme: Hepatitis-free future with a strong focus on perinatal transmission. Read more about their efforts here. You can register to join their global virtual event, WHO Commemoration of World Hepatitis Day, on July 28th 1pm-3:15pm CEST here. Hep B United - Yesterday, in anticipation of World Hepatitis Day, Hep B United kicked off a week of action with a call where we heard about the importance of hepatitis B elimination from hepatitis B advocates and representatives

    http://www.hepb.org/blog/292-million-people-worldwide-hepatitis-b-feel-alone/
  • Know Your ABCs

    … your doctor if you are a pregnant woman with symptoms as a more severe HEV infection can occur. Many individuals do not show symptoms of hepatitis E infection1. Additionally, most individuals recover from HEV, and it rarely progresses to chronic infection. Read this blog for a detailed comparison of hepatitis B and hepatitis E! Here is a simple table to further help you understand the differences among hepatitis A, B, C, D, and E. Prevention Fortunately, hepatitis viruses are preventable. Hepatitis A is preventable through a safe and effective vaccine. The Centers for Disease Control and Prevention (CDC) recommend that children be vaccinated for HAV at 12-23 months or at 2-18 years of age for those who have not previously been vaccinated. The vaccine is given as two doses over a 6-month span1. This vaccine is recommended for all people living with hepatitis B & C infections Hepatitis B is also preventable through a safe and effective vaccine. The vaccine includes 3 doses over a period of 6 months, and in the U.S. there is a 2-dose vaccine that can be completed in 1-month1,3. Read more here, if you would like to know more about the vaccine series schedule. Hepatitis C does not have a vaccine, however, the best way to prevent HCV is by avoiding risky behaviors like injecting drugs and promoting harm reduction practices. While there is no vaccine, curative treatments are available for HCV1. Hepatitis Delta does not have a vaccine, but you can prevent it through vaccination for hepatitis B1,3. Hepatitis E does not have a vaccine available in the United States. However, there has been a vaccine developed and licensed in China1,2.   References https://www.cdc.gov/hepatitis/index.htm https://www.who.int/news-room/q-a-detail/what-is-hepatitis https://www.hepb.org/what-is-hepatitis-b/the-abcs-of-viral-hepatitis/  

    http://www.hepb.org/blog/know-your-abcs/
  • Clinical Trials Finder - Find A Clinical Trial Near You!

      The Hepatitis B Foundation is thrilled to announce the addition of a new clinical trials search tool to our website! People around the world can now easily search for clinical trial opportunities on the Hepatitis B Foundation website. Created by Antidote - a company that designs technologies to link patients with scientific opportunities - the new tool filters through all of the trials listed in the U.S. National Library of Medicine’s database of private and publicly funded studies. Searching for clinical trials can be time-consuming and confusing to navigate, but this resource eases the process by finding the best trials for you based upon a series of questions. You can now search for hepatitis B, hepatitis D and liver cancer clinical trials with a few simple clicks! Clinical trials are a series of research phases that a new drug must go through in order to be approved for widespread use. They are an essential to proving that a treatment is safe and effective for the larger population. Generally, these trials take 10-15 years to go from the laboratory to the public, but delays in finding or retaining enough volunteers can extend the process.  Diverse participation in clinical trials is needed to make sure that a treatment is effective for all groups. Research diversity matters greatly for several reasons. Studies have shown that different races and ethnicities may respond differently to a certain medication. In addition, researchers need to examine the impact of the medication on the populations that will eventually use them. According to data from the U.S. Food and Drug Administration (US FDA), individuals from Africa and Asia or of African and Asian descent consistently remain underrepresented in clinical trials; these populations are also disproportionately impacted by hepatitis B.  If these groups are underrepresented in trials for hepatitis B treatments, new drugs may not be as effective in these communities, or there may be side effects that

    http://www.hepb.org/blog/clinical-trials-finder-find-clinical-trial-near/
  • Drug Update: Replicor Researchers Talk to HBF About Potential New Hep B and D Treatment

    … planning to assess other immunotherapies, the effectiveness of which we believe will be similarly improved with HBsAg clearance as we have demonstrated for pegIFN. 9. With regard to hepatitis delta, is there a difference in the mechanism for how it works? REP 2139 is also potently active against HDV infection and is able to rapidly eliminate HDV RNA, normalize liver function and reverse the liver inflammation associated with HBV / HDV co-infection. The completed follow-up results from our long term follow-up study of co-infected participants treated with REP 2139 and pegIFN show complete control of HDV infection at 3.5 years follow-up in the absence of all therapy in a large proportion of patients. In many patients this control of HDV infection was associated with functional cure of HBV and in some patients with virologic control of HBV. This potent effect against HDV infection is assumed to be driven not only from the effect of REP 2139 on SVP (which also forms the envelope of the HDV virus) but on the ability of REP 2139 to interact with different forms of the hepatitis delta antigen protein essential for HDV replication and assembly. Thank you to Dr. Vaillant for taking the time to talk to us about REP 2139. The results look promising! We look forward to learning more from continuing and new trials with REP 2139, used alone and in combination with antivirals and immune modulators. We know the hepatitis B virus is challenging, but those living with chronic HBV look forward to a day when there are therapies resulting in a durable loss of surface antigen and sustained viral suppression in a reasonable, finite amount of time. 

    http://www.hepb.org/blog/drug-update-replicor-researchers-talk-hbf-potential-new-hbvhdv-treatment/
  • Hepatitis B Foundation hails decision by U.S. Public Health Service Corps to accept future applicants living with chronic hepatitis B infection and HIV

    The Foundation brought attention to a discriminatory practice two years ago after receiving a complaint from a person living with hepatitis B.  Doylestown, Pa., Dec. 2, 2021 – The Hepatitis B Foundation applauds the decision of the U.S. Public Health Service Commissioned Corps to accept future applicants living with chronic hepatitis B infection and HIV. The USPHS Commissioned Corps announced the change yesterday (Dec. 1), which was World AIDS Day. Previously, HIV and hepatitis B infection were both considered disqualifying medical conditions. This new decision reflects the latest scientific evidence and opens the door for applicants with hepatitis B and HIV to serve as uniformed Public Health Service officers. The Hepatitis B Foundation became aware of the prohibition of applicants with hepatitis B in late 2020, when an individual with hepatitis B applied to serve but was denied due to his hepatitis B infection and contacted the Foundation. Since then, the Foundation has worked alongside partners advocating for a change in this policy. Hepatitis B Foundation leadership met with senior administration officials to raise awareness and urge them to prioritize this issue. Through legislative advocacy, the Foundation was able to get report language included in the FY 2022 House Labor-HHS Appropriations report urging the USPHS to allow officers with hepatitis B to serve in the Commissioned Corps. “We are excited that people living with hepatitis B and HIV can now serve in the USPHS Commissioned Corps,” Chari A. Cohen, DrPH, MPH, president of the Hepatitis B Foundation said. “It will be so gratifying to explain to future consult callers that a hepatitis B infection will not stand in the way of their professional aspirations.” This new win comes alongside a string of successes to end discrimination against people living with hepatitis B in the U.S. In 2012, the CDC published updated recommendations for healthcare providers and students with hepatitis B, clearly stating that hepatitis B was not a reason to deny or dismiss a person from practicing in a healthcare profession. In 2013, a landmark decision by the U.S. Department of Justice successfully made hepatitis B a protected condition under the Americans with Disabilities Act (ADA). “There is still work to be done to end discrimination against people living with hepatitis B. The Foundation is working with partners to advocate for the inclusion of people with hepatitis B in the U.S. military,” Dr. Cohen said. “But this decision brings us one step closer to universal equity, inclusion and justice for people with hepatitis B and HIV in the U.S.” About Hepatitis B: Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks and injures the liver. Each year up to 1 million people die from hepatitis B worldwide, even though it is preventable and treatable. Hepatitis B is a “silent epidemic” because most people do not have symptoms when they are newly or chronically infected. Thus, they can unknowingly infect others and continue the spread of hepatitis B. For people who are chronically infected but don’t have any symptoms, their livers are still being silently damaged, which can develop into serious liver disease such as cirrhosis or liver cancer.

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-hails-decision-by-u-s-public-health-service-corps-to-accept-future-applicants-living-with-chronic-hepatitis-b-infection-and-hiv/
  • Hepatitis B Foundation Announces 2019 Baruch S. Blumberg Prize Winner

    Dr. Christoph Seeger of Fox Chase Cancer Center Recognized for His Contributions to the Science of Hepatitis B DOYLESTOWN, PA (November 12, 2018) The Hepatitis B Foundation has named Christoph Seeger, PhD, the recipient of its 2019 Baruch S. Blumberg Prize for excellence in hepatitis B research. Dr. Seeger is a Professor and Senior Scientist at Fox Chase Cancer Center in Philadelphia. Dr. Seeger will receive the award at the Hepatitis B Foundation’s annual Crystal Ball Gala planned April 26, 2019 at Blue Bell Country Club in Blue Bell, PA. The Baruch S. Blumberg Prize is the Hepatitis B Foundation’s highest honor, given to publicly recognize and appreciate the outstanding contributions made by an individual to significantly advance the science and medicine of hepatitis B. It is named for Baruch S. Blumberg, who received the Nobel Prize for his discovery of the hepatitis B virus, and who was instrumental to the work of the Hepatitis B Foundation. “Dr. Seeger’s outstanding contributions to hepatitis B molecular biology have had implications not only for hepatitis B, but for all viruses,” said Timothy Block, PhD, president of the Hepatitis B Foundation and its Baruch S. Blumberg Institute. “We are proud to recognize the impact of his work in hepatitis B research.” Dr. Seeger is credited with demonstrating one of the essential enzymatic activities of the HBV polymerase, its primase activity. In the process of this discovery, he showed that the protein is covalently attached to viral RNA, which was then very unexpected. The finding has implications for some other viruses, as well. Dr. Seeger’s work at Fox Chase Cancer Center has focused on the biology of human pathogenic viruses with an emphasis on HBV. Professor Seeger's investigations have led to the identification of the signals required for reverse transcription of the viral DNA and provided the basis for the current model for HBV replication. His laboratory also expressed the HBV polymerase in enzymatically active form in the presence of the heat shock protein 90 complex. In line with his interest in HBV biology, the goal of his current research is to investigate a novel approach to inactivate covalently closed circular (ccc) DNA, which could improve current antiviral therapies and lead to a cure for chronic infections. He earned his PhD from the University of Basel, Switzerland. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at http://hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at www.facebook.com/hepbfoundation or call 215-489-4900.

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-announces-2019-baruch-s-blumberg-prize-winner/
  • Executive Director Retires After 25 Years of Service

    Co-founder Joan Block helped create the nation’s leading nonprofit research and disease advocacy organization dedicated to hepatitis B DOYLESTOWN, Pa. (April 2017) – The Hepatitis B Foundation has announced that its co-founder Joan Block, RN, BSN, is retiring as executive director in June 2017. After 25 years of service, Block is stepping down to pass the torch to a new director who will lead the foundation’s next quarter century of discovery. An interim director will be named as the board of directors conducts a nationwide search for a permanent replacement. Joan Block, RN, BSN “Joan Block has been an inspiration and a guiding force for the Hepatitis B Foundation for 25 years, and her accomplishments made it possible for us to reach the point we are at today – a trusted global authority for hepatitis B and a beacon of hope for the 240 million people affected worldwide,” said Joel Rosen, Esq., chairman of the foundation’s board of directors. “The foundation owes her an immense debt of gratitude for her dedication, and we are fortunate that we will continue to benefit from her wisdom and experience while we search for the next leader to shepherd us into the future.” Block and her husband, Dr. Timothy Block, with Paul and Janine Witte, created the Hepatitis B Foundation in 1991 in New Hope, PA. Their goal was to find a cure for hepatitis B, the world’s most common serious liver infection, and help improve the quality of life for those affected. In the years since, the foundation has grown from a grassroots effort in Pennsylvania into the nation’s leading nonprofit research and disease advocacy organization for hepatitis B with a global reach. Under Block’s leadership, the foundation has created many comprehensive programs, including a website (www.hepb.org) that attracts more than one million unique visitors from 150 countries, multi-platform, multi-lingual educational materials, newsletters, and email and telephone helplines. It has been at the forefront in developing successful national and international public health campaigns, and leading a robust advocacy presence in Washington, DC that has resulted in hepatitis B becoming a protected condition under the Americans With Disabilities Act to prevent discrimination, and increased federal funding for hepatitis B and liver cancer research. “The past 25 years have been immensely rewarding with many exciting and challenging experiences,” said Block. “The foundation’s success has been made by possible by many people whom I have had the privilege to work with. Individually and collectively each person has inspired and enriched me, and those relationships are what I will treasure most from this amazing journey, and will miss the most.” Block’s health and advocacy career began when she was a nursing student at Thomas Jefferson University and continued as she worked as a pediatric oncology nurse, adult cardiac care nurse and nurse educator. Today, while she serves on the boards of other nonprofit organizations, her commitment to the Hepatitis B Foundation remains a personal priority. Although Block is stepping down as executive director of the foundation, she will continue to serve as an advocate for its mission to find a cure and make hepatitis B history. In 2003, the foundation established an affiliated research institute, renamed the Baruch S. Blumberg Institute in 2013 in memory of its co-founder who won the Nobel Prize for his discovery of the hepatitis B virus. Today, the Blumberg Institute supports the nation’s largest concentration of nonprofit scientists focused on hepatitis B and liver cancer drug discovery. It also coordinates, with the foundation, the International Hepatitis B Meeting that rotates annually between North America, Europe and Asia. Both the Hepatitis B Foundation and Baruch S. Blumberg Institute are headquartered in the Pennsylvania Biotechnology Center in Buckingham, PA. The Biotech Center was established in 2006 to serve as the home of the foundation and is managed by the Blumberg Institute. It is a life-sciences incubator and accelerator that offers state-of-the-art laboratory and office space to nonprofit research companies and biotech companies.   About Hepatitis B: Hepatitis B is the world’s most common serious liver infection and the primary cause of liver cancer, which is the 2nd leading cause of cancer deaths in the world. Two billion people (or 1 in 3) have been infected with the hepatitis B virus, more than 240 million are chronically infected, and almost 1 million people die each year from hepatitis B-related liver failure and liver cancer. In the U.S., 1 in 20 Americans has been infected with hepatitis B, and an estimated 2 million are chronically infected. The hepatitis B virus is transmitted through blood, unprotected sex, unsterile needles, and from an infected mother to her newborn during delivery. Although hepatitis B is preventable and treatable, there is still no complete cure for this deadly liver infection. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at www.hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at www.facebook.com/hepbfoundationor call 215-489-4900.   # # #

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-executive-director-retires-after-25-years-of-service/
  • Hepatitis B Foundation Launches #justB Storytelling Campaign

    Hepatitis B Foundation Launches #justB Storytelling Campaign A national resource of stories shared by real people affected by hepatitis B DOYLESTOWN, PA (January 2017) – Few people know about hepatitis B or the stories of the two million Americans living with the serious liver infection. This will change beginning January 2017 as the Hepatitis B Foundation unveils its #justB national storytelling campaign with real people sharing their stories about hepatitis B. The goal is to put a human face on this disease in order to increase public awareness, decrease stigma and discrimination, and to promote testing and treatment for hepatitis B, which will ultimately save lives. Stories will be featured each month on the foundation’s website at hepb.org/justb. Hepatitis B has infected 1 out of 3 people worldwide – or 2 billion people in total. Of this number an estimated 240 million people are chronically infected and live with an increased risk of dying prematurely from cirrhosis, liver failure and liver cancer. Two-thirds of these people don’t know they’re infected with the hepatitis B virus, which is spread through blood, unprotected sex, unsterile needles, and from an infected mother to her newborn during childbirth. Although there is still no complete cure, the good news is that hepatitis B is preventable and treatable. The first #justB video to debut is ‘Janet and Kurt's Story,’ which shares the experience of a couple who learn that the baby they plan to adopt is being born to a woman infected with hepatitis B. They describe their initial fear and panic, their frantic search for information, and their efforts to make sure the baby is vaccinated in the delivery room to break the mother-to-child infection cycle that leads to most of the new hepatitis B infections worldwide. In the months to come, nearly 20 individuals from across the U.S. will be featured in storytelling videos, sharing their experiences about being diagnosed with hepatitis B and the struggle to receive adequate treatment, the stigma and discrimination they face, and their courage in living with this chronic liver disease. Family members also share the pain of caring for and losing loved ones due to hepatitis B. Each story is a powerful reflection of the enormous impact that hepatitis B has on the lives of hundreds of millions people around the world. The Hepatitis B Foundation is partnering with Philippa Wharton, a video producer headquartered in New York City, and the StoryCenter, a nonprofit organization that started the global digital storytelling movement, to produce the #justB videos. The foundation has also collaborated with the Association of Asian Pacific Community Health Organizations (AAPCHO) in the development and promotion of this national initiative. “There is no better way to raise public understanding about the true impact of hepatitis B than through personal stories,” said Joan Block, RN, BSN, executive director and co-founder of the Hepatitis B Foundation. “Hearing from real people will help make hepatitis B real. And this will help us to make hepatitis B an urgent public health priority, with the goal to eliminate hepatitis B once and for all.” The #justB storytelling campaign is funded by educational grants from Arbutus Biopharma, focused on hepatitis B drug discovery, and Dynavax Technologies, dedicated to immunotherapies. For more information or to view the videos, visit hepb.org/justB. About Hepatitis B: Hepatitis B is the world’s most common serious liver infection and the primary cause of liver cancer, which is the 2nd leading cause of cancer deaths in the world. Two billion people (or 1 in 3) have been infected with the hepatitis B virus, more than 240 million are chronically infected, and almost 1 million people die each year from hepatitis B-related liver failure and liver cancer. In the U.S., 1 in 20 Americans has been infected with hepatitis B, and an estimated 2 million are chronically infected. The hepatitis B virus is transmitted through blood, unprotected sex, unsterile needles, and from an infected mother to her newborn during delivery. Although hepatitis B is preventable and treatable, there is still no complete cure for this deadly liver infection. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at facebook.com/hepbfoundation or call 215-489-4900. # # #

    https://www.hepb.org/news-and-events/news-2/justb-launch/
  • Hepatitis B Research Pioneer Dr. Bud Tennant Leaves Behind a Distinguished Scientific Legacy

    Dr. Tennant was a great scientist, a man of valor who will be missed by the hepatitis community DOYLESTOWN, Pa. (November 2016)- Bud C. Tennant, DVM, a pioneer in developing the woodchuck animal model for the study of hepatitis B, and distinguished member of the Hepatitis B Foundation’s Scientific and Medical Advisory Board and former James Law Professor of Comparative Medicine from the University of Cornell, College of Veterinary Medicine, passed away on November 16. Dr. Tennant leaves an enormous scientific legacy of contributions to advancing the science and medicine of hepatitis B, for which he was publicly recognized with the prestigious Baruch S. Blumberg Prize by the foundation at its annual Crystal Ball in April of this year. Dr. Bud Tennant “Humanity owes a tremendous debt to Dr. Tennant for his pioneering work in hepatitis research, which has been among the most important in the field,” said Timothy Block, Ph.D., co-founder and president of the Hepatitis B Foundation and its research arm, the Baruch S. Blumberg Institute. “We are proud that he served on our Scientific Advisory Board since his years of dedicated research have made it possible for us to envision a world without hepatitis B.” Dr. Tennant's work with hepatitis B infection in woodchucks led to the development of the first and only animal model successfully used to definitively identify potential and approved therapeutics for hepatitis B.While on the faculty of Cornell University College of Veterinary Medicine, he was contacted regarding a new virus infecting woodchucks that was closely related to the human hepatitis B virus (HBV). He was instrumental in identifying, testing and maintaining a colony of woodchucks for use in HBV research, in conjunction with the National Institute of Allergy and Infectious Diseases of the NIH. Over the next 31 years, the woodchuck model was used on nearly every drug licensed by the U.S. FDA for hepatitis B treatment and for most of the HBV drug candidates. "He was a great scientist and a man of valor and impeccable honesty and full of insight. We did a lot of great things together over the last 20 plus years," said Raymond Schinazi, Ph.D., Professor of Pediatrics and director of the Laboratory of Biochemical Pharmacology at Emory University, and member of the Hepatitis B Foundation Scientific and Medical Advisory Board. "The hepatitis community and I will miss him greatly." In 2013, Dr. Tennant retired from the University of Cornell, College of Veterinary Medicine, and his legendary woodchuck colony was transferred to the Roswell Park Cancer Institute (RPCI) in Buffalo, NY. He continued to consult at RPCI and with other academic and commercial laboratories on the use of the woodchuck animal model in antiviral drug development and on viral causes of liver cancer. Dr. Tennant served as President of the American College of Veterinary Internal Medicine and was a recipient of its Robert W. Kirk Distinguished Service Award; was a Visiting Scholar at the University of Cambridge and Visiting Professor at Georgetown University School of Medicine; and served in the U.S. Army Veterinary Corps at the Walter Reed Army Institute of Research, Division of Basic Surgical Research. He also served on the Scientific and Medical Advisory Board of the Hepatitis B Foundation for 18 years. A celebration of Dr. Tennant’s life will be held at Kendal at Ithaca, New York, on January 28, 2017 at 2:00 pm. In lieu of flowers, the family has graciously requested that donations may be made in Dr. Tennant’s memory to the Hepatitis B Foundation, 3805 Old Easton Road, Doylestown, PA 18902. The full obituary is available at www.legacy.com/obituaries/theithacajournal/obituary.aspx?n=bud-christopher-tennant&pid=182819897&fhid=7263. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at http://hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at www.facebook.com/hepbfoundation or call 215-489-4900. ###

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-research-pioneer-dr-bud-tennant-leaves-behind-a-distinguished-scientific-legacy/